Additionally, S1PR1 radioligand has gained significant interest for in vivo targeted imaging of inflammation in brain diseases, with the recent FDA-approved S1PR1-based treatments such as Fingolimod, Siponimod, and Ozanimod (18) for multiple sclerosis. Here, S1PR1 is linked to brain disorder.